M. E. Anderson, Orthopaedic Oncology Surgeon, Beth Israel Deaconess Medical Center and Boston Children’s Hospital, Boston, MA, USA
J. S. Wu, Musculoskeletal Radiologist, Beth Israel Deaconess Medical Center, Boston, MA, USA
S. O. Vargas, Staff Pathologist, Boston Children’s Hospital, Boston, MA, USA
Megan E. Anderson MD, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215 USA, Email: email@example.com
A note from the Editor-in-Chief: We are pleased to present the next installment of our CORR® Tumor Board column, which provides multidisciplinary perspective on the themes raised in selected CORR® tumor papers. In this column, we will discuss the implications of the highlighted article from the varied disciplines of the Tumor Board members: Orthopaedic surgery, pathology, and radiology. This month’s column features the study “Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines” by Collier and colleagues available at: DOI: 10.1007/s11999.0000000000000059.
The authors certify that neither they, nor any members of their immediate families, have any commercial associations (such as consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request.
The opinions expressed are those of the writers, and do not reflect the opinion or policy of CORR® or The Association of Bone and Joint Surgeons®.
This CORR Tumor Board column refers to the article available at DOI: 10.1007/s11999.0000000000000059.
Received April 09, 2018
Accepted April 24, 2018